Celltrion Pharm's Godex Maintains Top Spot in Outpatient Liver Medication Market for Over 10 Years

Market Share Reaches 30.4% in April

MASLD Symposium Held for Liver Disease

Celltrion Pharm announced on May 19 that its liver disease medication 'Godex Capsule' (a combination drug containing orotic acid carnitine and six other ingredients) has maintained the top spot in the domestic outpatient prescription market for liver medications for over 10 years.

Godex Capsule. Celltrion Pharmaceuticals

According to UBIST data, Godex achieved approximately 7.4 billion won in outpatient prescription sales in April this year, with a market share of 30.4%. Since October 2015, Godex has led the domestic outpatient prescription market for liver medications for 127 consecutive months. The company explained that it has continued to drive performance growth, leveraging activities such as joint promotions with Chong Kun Dang.

Godex is a liver medication prescribed for patients with liver disease who show elevated transaminase (SGPT) levels, which indicate liver cell damage. Based on clinical results related to the normalization of liver cell damage markers and the improvement of fatty liver, it has been actively used in medical settings.

Furthermore, Godex can help improve fatty liver by restoring mitochondrial function, which plays a role in energy production and ammonia detoxification within liver cells, as well as by increasing the efficiency of fatty acid breakdown and utilization. According to the company, clinical studies have shown that alanine aminotransferase (ALT) levels tend to rise again after discontinuation of the medication, and that the incidence of side effects with long-term use is low.

Celltrion Pharm hosted the '9th Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Symposium' at Symphony Hall, Hidden Cliff Jeju, on May 16–17. The sessions were chaired by Professor Lee Jinwoo of Inha University College of Medicine, Professor Kim Hyungjun of Chung-Ang University College of Medicine, and Professor Jeon Daewon of Hanyang University College of Medicine. Presentations were delivered by Professor Lee Hana of Chung-Ang University College of Medicine (advances in MASLD diagnosis and treatment), Professor Shin Seunggak of Gachon University College of Medicine (risk factors for liver fibrosis and MASLD clinical outcomes), Professor Kim Seungup of Yonsei University College of Medicine (clinical evidence for carnitine complexes and liver-protective effects), and Professor Jang Heejoon of Seoul National University College of Medicine (the relationship between liver cancer and MASLD, and liver cancer treatment).

A Celltrion Pharm representative stated, "Godex has maintained its No. 1 position in the domestic outpatient prescription market for liver medications for over 10 years, once again proving its differentiated product competitiveness and market presence. We will continue to carry out a variety of academic activities that can help the clinical field, while striving to further enhance the value of our products."

This content was produced with the assistance of AI translation services.